Видео ютуба по тегу Satellos Bioscience

Satellos Bioscience (MSCL) Encouraging Phase 1b Trial Data: Adults with Duchenne Muscular Dystrophy
Satellos Bioscience (MSCL) Encouraging Phase 1b Trial Data: Adults with Duchenne Muscular Dystrophy
EP 190: Targeting regeneration to tackle Duchenne Muscular Dystrophy with Frank Gleeson of Satellos
EP 190: Targeting regeneration to tackle Duchenne Muscular Dystrophy with Frank Gleeson of Satellos
Satellos Bioscience (MSCL) - Chief Technology Officer Phil Lambert Discusses SAT-3153 Study Results
Satellos Bioscience (MSCL) - Chief Technology Officer Phil Lambert Discusses SAT-3153 Study Results
Satellos Bioscience (MSCL) CEO Frank Gleeson, CMO Dr. Wildon Farwell: Trial Update & Catalysts
Satellos Bioscience (MSCL) CEO Frank Gleeson, CMO Dr. Wildon Farwell: Trial Update & Catalysts
Satellos Bioscience aims to advance the clinical development of medicine related to muscle disorders
Satellos Bioscience aims to advance the clinical development of medicine related to muscle disorders
Satellos BioScience подает патентную заявку, стремясь помочь в лечении мышечной дистрофии Дюшенна
Satellos BioScience подает патентную заявку, стремясь помочь в лечении мышечной дистрофии Дюшенна
Phil Lambert, Ph.D., chief scientific officer, Satellos Bioscience Inc., Part 1
Phil Lambert, Ph.D., chief scientific officer, Satellos Bioscience Inc., Part 1
Новый вариант лечения мышечной дистрофии Дюшенна (SAT-3247) показал многообещающие результаты на ...
Новый вариант лечения мышечной дистрофии Дюшенна (SAT-3247) показал многообещающие результаты на ...
Family Forum 2024: A Conversation with Satellos
Family Forum 2024: A Conversation with Satellos
Satellos DMD therapy - 3D animation
Satellos DMD therapy - 3D animation
Satellos (MSCL) - Presentation, Deep Dive and Q&A with CEO Frank Gleeson
Satellos (MSCL) - Presentation, Deep Dive and Q&A with CEO Frank Gleeson
Webinar: Exploring Muscle Regeneration - A New Approach with Satellos
Webinar: Exploring Muscle Regeneration - A New Approach with Satellos
Satellos Bioscience (MSCL) CEO Frank Gleeson: Phase 1 & 2 Milestones for 2024-2025 targeting DMD
Satellos Bioscience (MSCL) CEO Frank Gleeson: Phase 1 & 2 Milestones for 2024-2025 targeting DMD
Satellos Virtually Opens the Market, September 28, 2021
Satellos Virtually Opens the Market, September 28, 2021
Highlighting Early-Stage Promising Data of AAK1 Inhibitor SAT-3247 in Duchenne Muscular Dystrophy
Highlighting Early-Stage Promising Data of AAK1 Inhibitor SAT-3247 in Duchenne Muscular Dystrophy
Satellos Bioscience (MSCL) CEO Frank Gleeson: & CTO Phil Lambert - Deep Dive, Review & Outlook
Satellos Bioscience (MSCL) CEO Frank Gleeson: & CTO Phil Lambert - Deep Dive, Review & Outlook
Shaping the Future: Leadership and Vision at Satellos
Shaping the Future: Leadership and Vision at Satellos
EP 190: Targeting regeneration to tackle Duchenne Muscular Dystrophy with Frank Gleeson of Satellos
EP 190: Targeting regeneration to tackle Duchenne Muscular Dystrophy with Frank Gleeson of Satellos
New ways to treat Duchenne muscular dystrophy
New ways to treat Duchenne muscular dystrophy
Pioneering Duchenne Muscular Dystrophy Treatment with Satellos | Elijah Stacy & Dr. Rudnicki
Pioneering Duchenne Muscular Dystrophy Treatment with Satellos | Elijah Stacy & Dr. Rudnicki